Synonyms: aducanumab-avwa | Aduhelm® | BART | BIIB-037 | BIIB037
aducanumab is an approved drug (FDA (2021))
Compound class:
Antibody
Comment: Aducanumab is a fully human IgG1-kappa monoclonal antibody directed against the amyloid beta (Aβ) found in the amyloid plaques in the brain tissue of patients with Alzheimer's disease (AD).
Peptide sequences and structural information about this antibody are available from its IMGT/mAb-DB record. A patent search reveals Biogen Idec's patent submission WO2014089500 [2]. |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2021)) |
International Nonproprietary Names | |
INN number | INN |
9838 | aducanumab |
Synonyms |
aducanumab-avwa | Aduhelm® | BART | BIIB-037 | BIIB037 |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 479 |
Other databases | |
GtoPdb PubChem SID | 252166537 |
Search PubMed clinical trials | aducanumab |
Search PubMed titles | aducanumab |
Search PubMed titles/abstracts | aducanumab |
Wikipedia | Aducanumab |